Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1969 1
1999 1
2001 1
2002 4
2003 4
2004 1
2007 6
2008 7
2009 6
2010 12
2011 7
2012 10
2013 6
2014 9
2015 10
2016 10
2017 7
2018 8
2019 8
2020 8
2021 10
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

117 results
Results by year
Filters applied: . Clear all
Page 1
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Maemondo M, et al. Among authors: oizumi s. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. N Engl J Med. 2010. PMID: 20573926 Free article. Clinical Trial.
Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).
Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y. Okada M, et al. Among authors: oizumi s. Clin Cancer Res. 2019 Sep 15;25(18):5485-5492. doi: 10.1158/1078-0432.CCR-19-0103. Epub 2019 Jun 4. Clin Cancer Res. 2019. PMID: 31164373 Free article.
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations.
Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K, Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y. Ninomiya K, et al. Among authors: oizumi s. JTO Clin Res Rep. 2020 Oct 12;2(1):100107. doi: 10.1016/j.jtocrr.2020.100107. eCollection 2021 Jan. JTO Clin Res Rep. 2020. PMID: 34589972 Free PMC article. Review.
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.
Kunimasa K, Oka T, Hara S, Yamada N, Oizumi S, Miyashita Y, Kamada R, Funamoto T, Kawachi H, Kawamura T, Inoue T, Kuhara H, Tamiya M, Nishino K, Matsunaga T, Imamura F, Fujita M, Kumagai T. Kunimasa K, et al. Among authors: oizumi s. Lung Cancer. 2021 Mar;153:186-192. doi: 10.1016/j.lungcan.2020.10.021. Epub 2020 Nov 16. Lung Cancer. 2021. PMID: 33277055
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
Ikezawa Y, Asahina H, Oizumi S, Watanabe M, Takamura K, Kawai Y, Yamada N, Harada T, Kinoshita I, Fujita Y, Miyauchi E, Ogi T, Amano T, Furuta M, Sakakibara-Konishi J, Nishihara H, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Ikezawa Y, et al. Among authors: oizumi s. Cancer Chemother Pharmacol. 2017 Nov;80(5):955-963. doi: 10.1007/s00280-017-3432-4. Epub 2017 Sep 13. Cancer Chemother Pharmacol. 2017. PMID: 28905108 Free article. Clinical Trial.
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
Asahina H, Tanaka K, Morita S, Maemondo M, Seike M, Okamoto I, Oizumi S, Kagamu H, Takahashi K, Kikuchi T, Isobe T, Sugio K, Kobayashi K. Asahina H, et al. Among authors: oizumi s. Clin Lung Cancer. 2021 Mar;22(2):147-151. doi: 10.1016/j.cllc.2020.09.023. Epub 2020 Oct 16. Clin Lung Cancer. 2021. PMID: 33199228 Clinical Trial.
Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.
Horinouchi H, Atagi S, Oizumi S, Ohashi K, Kato T, Kozuki T, Seike M, Sone T, Sobue T, Tokito T, Harada H, Maeda T, Mio T, Shirosaka I, Hattori K, Shin E, Murakami H. Horinouchi H, et al. Among authors: oizumi s. Cancer Med. 2020 Sep;9(18):6597-6608. doi: 10.1002/cam4.3306. Epub 2020 Jul 30. Cancer Med. 2020. PMID: 32730697 Free PMC article.
Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M, Sakakibara-Konishi J, Kikuchi H, Yokouchi H, Nishihara H, Minemura H, Harada M, Yamazaki S, Akie K, Fujita Y, Takamura K, Kojima T, Harada T, Minami Y, Watanabe N, Oizumi S, Suzuki H, Nishimura M, Dosaka-Akita H, Isobe H; Hokkaido Lung Cancer Clinical Study Group. Furuta M, et al. Among authors: oizumi s. Oncologist. 2019 Nov;24(11):e1172-e1179. doi: 10.1634/theoncologist.2018-0676. Epub 2019 May 8. Oncologist. 2019. PMID: 31068386 Free PMC article.
Numb has distinct function in lung adenocarcinoma and squamous cell carcinoma.
Kikuchi H, Sakakibara-Konishi J, Furuta M, Kikuchi E, Kikuchi J, Oizumi S, Hida Y, Kaga K, Kinoshita I, Dosaka-Akita H, Nishimura M. Kikuchi H, et al. Among authors: oizumi s. Oncotarget. 2018 Jun 29;9(50):29379-29391. doi: 10.18632/oncotarget.25585. eCollection 2018 Jun 29. Oncotarget. 2018. PMID: 30034624 Free PMC article.
117 results